Investigators Seek FREEDOM From Uncertainly Of Late-Loss Significance
This article was originally published in The Gray Sheet
Executive Summary
The ongoing FREEDOM trial will help clarify the importance of late lumen loss as a comparative measure of drug-eluting stent efficacy, according to Cardiovascular Research Foundation webcast participants
You may also be interested in...
Cypher Edges Out Taxus In A Meta-Analysis Of Six Head-To-Head Trials
A meta-analysis of six drug-eluting stent trials suggests that sirolimus-elutings stents are associated with a lower risk of restenosis and target vessel revascularization than paclitaxel-eluting stents
Cypher Edges Out Taxus In A Meta-Analysis Of Six Head-To-Head Trials
A meta-analysis of six drug-eluting stent trials suggests that sirolimus-elutings stents are associated with a lower risk of restenosis and target vessel revascularization than paclitaxel-eluting stents
Boston Scientific, J&J Dwell In Separate REALITY; Data Swamps ACC
Johnson & Johnson is emphasizing Cypher's low thrombosis rates after the sirolimus-eluting stent failed to show clinical superiority over Boston Scientific's Taxus